Boston Scientific Corporation [NYSE: BSX] stock went up by 0.34% or 0.13 points up from its previous closing price of $38.17. The stock reached $38.30 during the last trading session. During the course of the last 5 trading session in the week, BSX share price went up during 2 out of 5 days, that way gaining +0.09% in the period of the last 7 days.

BSX had two major price movements with the latest trading session as the price jumped to a high of $38.56, at one point touching $38.125. The latest high is set lower that the high price recorded in the period of the last 52 weeks, set at $38.56. The 52-week high currently stands at $43.84 distance from the present share price, noting recovery 0.16% after the recent low of $31.56.

Boston Scientific Corporation [NYSE:BSX]: Analyst Rating and Earnings

Its stock price has been found in the range of 31.56 to 43.84. This is compared to its latest closing price of $38.17.

Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Wed 23 Oct (In 5 Days).

Fundamental Analysis of Boston Scientific Corporation [BSX]

Now let’s turn to look at profitability: with a current Operating Margin for Boston Scientific Corpor

ation [BSX] sitting at +17.68 and its Gross Margin at +65.94, this company’s Net Margin is now 13.90%. These measurements indicate that Boston Scientific Corporation [BSX] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 12.23, and its Return on Invested Capital has reached 10.70%. Its Return on Equity is 21.24, and its Return on Assets is 8.35. These metrics all suggest that Boston Scientific Corporation is doing well at using the money it earns to generate returns.

Turning to investigate this organization’s capital structure, Boston Scientific Corporation [BSX] has generated a Total Debt to Total Equity ratio of 80.86. Similarly, its Total Debt to Total Capital is 44.71, while its Total Debt to Total Assets stands at 33.60. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 6.46, and its Long-Term Debt to Total Capital is 55.04.

What about valuation? This company’s Enterprise Value to EBITDA is 22.62 and its Total Debt to EBITDA Value is 2.68. The Enterprise Value to Sales for this firm is now 5.90, and its Total Debt to Enterprise Value stands at 0.13. Boston Scientific Corporation [BSX] has a Price to Book Ratio of 5.61, a Price to Cash Flow Ratio of 159.76 and P/E Ratio of 38.68. These metrics suggest that this publicly-traded organization will not likely result in investment gains.

Shifting the focus to workforce efficiency, Boston Scientific Corporation [BSX] earns $306,969 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.22 and its Total Asset Turnover is 0.49. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.54 and its Current Ratio is 0.76. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.

Boston Scientific Corporation [BSX] has 1.39B shares outstanding, amounting to a total market cap of $53.09B. Its stock price has been found in the range of 31.56 to 43.84. At its current price, it has moved down by -12.64% from its 52-week high, and it has moved up 21.36% from its 52-week low.

This stock’s Beta value is currently 0.79, which indicates that it is 1.72% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 38.27. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Boston Scientific Corporation [BSX] a Reliable Buy?

Shares of Boston Scientific Corporation [BSX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.